KALA BIO (NASDAQ:KALA) Earns Buy Rating from HC Wainwright

KALA BIO (NASDAQ:KALA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 123.88% from the company’s current price.

Separately, Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

KALA BIO Stock Down 0.9 %

KALA BIO stock opened at $6.70 on Friday. The company has a current ratio of 2.15, a quick ratio of 3.07 and a debt-to-equity ratio of 3.18. KALA BIO has a 1-year low of $4.21 and a 1-year high of $10.97. The company has a fifty day simple moving average of $6.02 and a 200 day simple moving average of $6.29. The company has a market cap of $30.89 million, a P/E ratio of -0.54 and a beta of -2.13.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Research analysts anticipate that KALA BIO will post -11.76 earnings per share for the current fiscal year.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is owned by institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.